Description:

Technoview®Arixtra®ControlLowisaplasmacontrolwithalowconcentrationofArixtra®*(~0.4µg/ml)foruseasaqualitycontrolsampleinresearchmeasurementsoffondaparinuxsodium.Itisoptimizedforusewithanti-Xachromogenicassaysand isfrequentlyusedinconjunctionwiththe Technoview®Arixtra® highcontrolandtheTechnoview®Arixtra® calibratorsetinthe Technochrom®anti-Xachromogenicassay.

*Fondaparinuxsodium istheactivesubstanceinArixtra®.

Advantages:

• 6vialsperkit-providescontrolsetwithalongshelflife
• AllowsforthevalidationofcalibrationcurvesforthemeasurementofArixtra® inplasma
• Optimizedforusewithanti-Xa(withoutexogeneousantithrombin) research assays

ControlSetComposition:

• 6x1mlvials

Controlmaterialislyophilizedandpreparedfrompooledhumancitratedplasmasupplementedwithalow concentrationofArixtra®.TheplasmacontainsstABIlizersbutnobactericideadditives.ItiscalibratedagainsttheInternationalStandardpreparation01/608.

Background:

Arixtra®(fondaparinuxsodium)InjectionisafactorXa(FXa)inhibitordrug.As asyntheticpentasaccharide,itischemicallysimilartolowmolecularweightheparin(LMWH),thoughitisselectiveforFXa.Morespecifically,itshighaffinityantithrombin(AT)binding allowsfor indirectinhibitionofFXa. Useofthisdrugsubstantiallylowerstheriskfor heparin-inducedthrombocytopenia(HIT)andithasnotbeenshownto reactwithHITantibodies.Itisprescribedbyahealthcareproviderandcanbeusedfor:

• prophylaxis ofvenousthromboembolism(VTE)aftermajororthopedicoraBDominalsurgery;or
• treatmentofacuteVTEwhenadmiNISTeredinconjunctionwithwarfarini.e.usedshort-termuntilthewarfarinbloodtestisinthetargetrange.

Inmostcases,Arixtra®doesnotrequireroutinemonitoring.However,itcanbemeasuredusingananti-Xaassaywithappropriatecalibrators(fondaparinuxsodium).Theactivityoffondaparinuxsodiumisexpressedinmgandcannotbecomparedtotheactivitiesofheparinor LMWH.NotethatthiscontrolisforresearchuseonlyintheUSandCanada.